09:15 AM EST - Avant Technologies Inc. : Announced a pivotal evolution in its business direction, emphasizing strategic partnerships through joint ventures and licensing agreements to advance treatments for a range of chronic and age-related conditions. In alignment with this refined mission, the company has applied for a corporate name change to better reflect its focus on pioneering biotechnology collaborations aimed at enhancing better health and longevity. This new model positions Avant at the forefront of collaborative biotech innovation, identifying promising cell lines from around the globe and forging alliances with leading biotech companies, scientists, and clinicians. By partnering rather than bearing the full burden of development costs and risks, Avant and its partners leverage complementary expertise and resources to accelerate the creation of groundbreaking therapies. Key areas of focus include diabetes, anti-aging, Alzheimer's disease, heart disease, cancer, kidney disease, other age-related conditions, and the promotion of longevity. Avant Technologies Inc.
shares O.AVAI are trading unchanged at $0.34.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=AVAI&qmodStoryID=7757943334058990
